GoASMozaffarianDRogerVL. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
2.
GijsbertsCSantemaBTAsselbergsFW. Women undergoing coronary angiography for myocardial infarction or who have multi-vessel disease have a worse prognosis than men. Angiology. 2016;67(6):571–581.
3.
GalvaoMKalmanJDeMarcoT. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail. 2006;12(2):100–107.
4.
KrumholzHMLarsonMLevyD. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72(3):310–313.
5.
CarrollJDCarrollEPFeldmanT. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. 1992;86(4):1099–1107.
6.
MasoudiFAHavranekEPSmithG. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. 2003;41(2):217–223.
7.
ZileMRBrutsaertDL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387–1393.
8.
LindenfeldJKrause-SteinraufHSalernoJ. Where are all the women with heart failure?J Am Coll Cardiol. 1997;30(6):1417–1419.
9.
ButlerJFonarowGCZileMR. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014;2(2):97–112.
10.
BergerJSRoncaglioniMCAvanziniFPangrazziITognoniGBrownDL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–313.
11.
CamiciPGCreaF. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–840.
12.
PepineCJAndersonRDSharafBL. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–2832.
13.
OnatACanG. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014;20(4):575–584.
VillablancaACJayachandranMBankaC. Atherosclerosis and sex hormones: current concepts. Clin Sci (Lond). 2010;119(12):493–513.
16.
WildmanRPKaplanRMansonJE. Body size phenotypes and inflammation in the Women’s Health Initiative Observational Study. Obesity (Silver Spring). 2011;19(7):1482–1491.
17.
HamiraniYSPandeySRiveraJJ. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis. 2008;201(1):1–7.
18.
KrintusMKozinskiMKubicaJSypniewskaG. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci. 2014;51(5):263–279.
19.
SinghSSinghHLoftusEVJrPardiDS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):382–393. e381:quiz e322.
20.
LangerRDPradhanADLewisCE. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women’s Health Initiative Observational Study. Thromb Haemost. 2005;93(6):1108–1116.
21.
RossouwJECushmanMGreenlandP. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women’s health initiative trials of hormone therapy. Arch Intern Med. 2008;168(20):2245–2253.
22.
RosanoGMVitaleCFiniM. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?Ann N Y Acad Sci. 2006;1092:341–348.
23.
LakoskiSGHerringtonDM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric. 2005;8(4):317–326.
24.
HowardBVHsiaJOuyangP. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation. 2004;110(2):201–206.
25.
KipKEMarroquinOCKelleyDE. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004;109(6):706–713.
26.
SoaresFHde SousaMB. Different types of physical activity on inflammatory biomarkers in women with or without metabolic disorders: a systematic review. Women Health. 2013;53(3):298–316.
27.
SpatzESCanavanMEDesaiMM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2(1):41–48.
28.
RidkerPMDanielsonEFonsecaFA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
29.
KatsikiNMikhailidisDP. Emerging Vascular Risk Factors in Women: any differences from men? [Published online September 4, 2015]. Curr Med Chem. 2015.
